Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (June 2018)

48 slides from Clearside Biomedical's investor presentation, Jun 20, 2018

  1. Slide 1: Corporate Presentation | June 2018

    Corporate Presentation | June 2018 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: A World Without Blindness

    Developing advanced clinical and preclinical product candidates, using a proprietary suprachoroidal treatment approach: Dedicated to developing treatments that restore and preserve vision for people with serious eye disease A World Without Blindness Unmet or underserved blinding eye diseases Patholo

  4. Slide 4: Privileged Organ Requiring Local Therapy

    Privileged Organ Requiring Local Therapy Limitations of Current Approaches to Local Administration Include: Corticosteroids reach unintended tissues, causing cataracts and glaucoma Multi-kinase inhibitors and gene therapies require precise placement at diseased tissue Certain drugs like complement i

  5. Slide 5: Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space

    Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space (“SCS”) VS Intravitreal & Periocular Suprachoroidal Fluid flows instantaneously and posteriorly Designed consistent suprachoroidal injection procedure Fluid with drug is absorbed into the choroid, RPE and retina

  6. Slide 6: Designed to Improve Ocular Distribution of Triamcinolone Acetonide

    Concentration (ng/g) Time, days Suprachoroidal CLS-TA The anterior segment is relatively spared following suprachoroidal dosing when compared to intravitreal dosing Designed to Improve Ocular Distribution of Triamcinolone Acetonide (TA) Over 10X the amount of TA remaining in the choroid and RPE foll

  7. Slide 7: Focused Pipeline of SCS Treatments For Multiple Blinding Eye Diseases

    INDICATION STUDY DRUG CURRENT STATUS Uveitis (macular edema associated with non-infectious uveitis) Suprachoroidal CLS-TA (corticosteroid triamcinolone acetonide) RVO (retinal vein occlusion) Suprachoroidal CLS-TA with anti-VEGF (Intravitreal Eylea®) DME (diabetic macular edema) Suprachoroidal CLS-T

  8. Slide 8: Major Near-Term Anticipated Milestones

    2018 2019 Uveitis RVO DME NDA review Phase 3 (SAPPHIRE) P3 Data (PEACHTREE) Phase 3 (TOPAZ) NDA Submission Publications Major Near-Term Anticipated Milestones Provide Multiple Potential Value-Inflection Points Topline P3 Data Analysis & Presentation P2 Data (TYBEE)

  9. Slide 9: Uveitis: One of the World's Leading Causes of Blindness

    UVEITIS One of the World’s Leading Causes of Blindness

  10. Slide 10: Current Treatment Paradigm

    Current Treatment Paradigm Note: TA = triamcinolone acetonide. Corticosteroids = most common treatment for all uveitis complications, including macular edema Periocular (Sub-tenon) 20 mg TA Sustained release dexamethasone implant (Ozurdex®) Intravitreal 4 mg TA Topical steroid for anterior uveitis 3

  11. Slide 11: The Opportunity In Treating Macular Edema with Uveitis

    The Opportunity In Treating Macular Edema with Uveitis Primary Need An approved therapy that targets vision impairment due to the underlying macular edema associated with all non-infectious uveitis The Problem Inflammation creates sight threatening macular edema No approved treatment for macular ede

  12. Slide 12: PEACHTREE Design for Pivotal Phase 3 Clinical Trial

    PEACHTREE Design for Pivotal Phase 3 Clinical Trial 3:2 randomization of suprachoroidal CLS-TA vs. sham injection; 160 patients total Primary endpoint at 6 months; superiority of best corrected visual acuity outcome from treatment SHAM Week-2 Day 0 Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24

  13. Slide 13: Primary Endpoint: Patients Gaining ≥15 ETDRS Letters

    46.9% (n=45) 15.6% (n=10) % patients gaining ≥15 ETDRS letters in BCVA from baseline Primary Endpoint ETDRS BCVA Proportion of patients in each arm gaining ≥ 15 ETDRS letters in BCVA from baseline at Week 24 p<0.001 N=96 N=64

  14. Slide 14: Secondary Endpoint: Mean Change in CRT at Week 24

    Secondary Endpoint Mean Change from Baseline in CRT at Week 24 in Microns Mean change from baseline at week 24 in central retinal thickness (microns) 479.8 µm: active arm; 518.0 µm: control arm p<0.001 Baseline retinal thickness (microns) N=96 N=64 ITT

  15. Slide 15: Secondary Endpoint: Mean Change in BCVA by Visit

    Secondary Endpoint Mean Change in BCVA in ETDRS Letters by Visit Mean change from baseline in BCVA in ETDRS letters read by visit Baseline ETDRS letters read 54.7: active arm; 53.6: control arm

  16. Slide 16: Subjects Reading ≥70 ETDRS Letters

    Percent patients Starting at week 8, approximately 50% of the suprachoroidal CLS-TA patients could read 70 or more ETDRS letters This improvement was sustained through the 24 weeks of the trial % Subjects Reading ≥70 ETDRS Letters (20/40)

  17. Slide 17: Resolution of Signs of Uveitis

    Resolution of signs of uveitis is clinically significant as most studies define their primary endpoint as reduction in signs Clear evidence suprachoroidal CLS-TA is working in all types of uveitis Directing drug to the disease is beneficial Resolution to Zero % Subjects Displaying Change to Zero at

  18. Slide 18: AE: Cataracts in CLS-TA and Sham Arms

    AE: Cataracts in CLS-TA and Sham Arms Percentage of cataract AEs Mar-2018 | NIU program | P3, PEACHTREE, trial | Topline data % Cataract AEs in Each Arm There were no treatments (i.e. surgeries) because of cataract AEs

  19. Slide 19: PEACHTREE Safety Summary

    PEACHTREE Safety Summary 97% of the randomized patients completed the trial No serious adverse events related to treatment Through 24 weeks, steroid-related elevated IOP adverse events were reported for 11.5% of patients in the CLS-TA treatment group, compared to no patients in the sham group 85-90%

  20. Slide 20: Next Steps

    Next Steps Based on feedback from end-of-Phase 2 meeting with the FDA, we believe PEACHTREE will be the only Phase 3 clinical trial required to support the filing of a New Drug Application (NDA) Detailed results from PEACHTREE will be presented at an upcoming medical conference Currently expect to s

  21. Slide 21: RVO: New Approach with CLS-TA + anti-VEGF

    RVO New Approach with CLS-TA + anti-VEGF

  22. Slide 22: Current Treatment Paradigm

    Current Treatment Paradigm Eylea, Lucentis, and off-label Avastin® Sustained release dexamethasone implant (Ozurdex®) Intravitreal Triamcinolone Acetonide 16.4 M patients Global RVO patients 2nd Line treatment 2.2 M patients US RVO patients 1 2 3 1st Line treatment

  23. Slide 23: The Opportunity In Treating RVO

    The Opportunity In Treating RVO Primary Needs More rapid and fuller resolution of macular edema to allow patients to recover as much vision as soon as possible The Problem Compared to uveitis and DME, macular edema following RVO is more severe, as is the attendant vision loss / potential vision gain

  24. Slide 24: TANZANITE Design for Phase 2 Trial

    Day 0 Month 1* Month 2* Month 3* Day 0 Month 1* Month 2* Month 3* Combination Arm Aflibercept Arm Evaluation period – 3 months Enrollment As needed Eylea Controlled, masked, randomized (1:1) study Patients RVO; Treatment naïve BCVA worse than 70 letters read; macular edema >310 µm on SD-OCT Single t

  25. Slide 25: 60% Fewer Additional Intravitreal Eylea Injections

    Intent-to-treat (ITT) population: N = 46 (23:23) Additional Intravitreal Eylea Injections p=0.013 Control arm: Intravitreal Eylea Active arm: Intravitreal Eylea + Suprachoroidal CLS-TA Number of Additional Injections 60% fewer additional intravitreal Eylea injections in the suprachoroidal CLS-TA + i

  26. Slide 26: Number of Patients Requiring Additional Treatment Reduced

    1 Based on post-hoc analysis Number of patients who received additional Intravitreal Eylea p=0.003 Intent-to-treat (ITT) population: N = 46 (23:23) 1 Control arm: Intravitreal Eylea Active arm: Intravitreal Eylea + Suprachoroidal CLS-TA Number of Patients Requiring Additional Treatment Reduced 69% f

  27. Slide 27: Improved Visual Acuity

    Improved Visual Acuity Suprachoroidal CLS-TA + Intravitreal Eylea resulted in more improved visual acuity at months 1, 2, 3 vs. intravitreal Eylea alone BCVA letter read: change from baseline M1 Intravitreal Eylea M1 Suprachoroidal CLS-TA + intravitreal Eylea M2 Intravitreal Eylea M2 Suprachoroidal

  28. Slide 28: Retinal Thickness Reductions

    Baseline 728 µm and 731 µm in the Aflibercept and Combination arms Aflibercept Arm; N=23 Combination Arm; N=23 Month 2 Month 1 Month 3 310 µm Retinal Thickness Reductions Suprachoroidal CLS-TA + intravitreal Eylea resulted in sustained retinal thickness reductions at months 1, 2, 3 vs. intravitreal

  29. Slide 29: Post-TANZANITE Evaluation

    Combination (n=20) 3 (15%) including Month 3 patients re-treated Monotherapy (n=11) 6 (55%) re-treated Eylea arm: 17% (n=4/23) Post-TANZANITE Evaluation 74% of patients who received combination therapy did not receive additional treatment through a minimum 9 months Combination arm: 74% (n=17/23)

  30. Slide 30: SAPPHIRE: Design for First Phase 3 RVO Clinical Trial

    SAPPHIRE Control arm Intravitreal Eylea; Q4Wk Combination arm Suprachoroidal CLS-TA + Intravitreal Eylea; Q12Wk Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week ww Week xx Week yy Week zz 2 Month primary efficacy endpoint Submit with 6 months data Continue to follow subjects out to 1 year PR

  31. Slide 31: TOPAZ: Class Label Objective in RVO

    If the primary endpoint is met in SAPPHIRE and TOPAZ, where CLS-TA has been used in combination with one of three anti-VEGF agents - Eylea, Lucentis and Avastin - the objective will be to seek a class label in the US where suprachoroidal CLS-TA can be used with any intravitreal anti-VEGF agent for t

  32. Slide 32: DME: Suprachoroidal CLS-TA Alone or in Combination with an Anti-VEGF Agent

    DME Suprachoroidal CLS-TA Alone or in Combination with an Anti-VEGF Agent

  33. Slide 33: Steroids Given Frequently to Treat DME

    Steroids Given Frequently to Treat DME CSME = Clinically significantly macular edema DME = diabetic macular edema National Center for Chronic Disease Preventions and Health Promotion: Division of Diabetes Translation. National Diabetes Statistical Report, 2014 International Diabetes Federation. IDF

  34. Slide 34: The Opportunity In Treating DME

    Anti-VEGF Therapy Protocol T indicates Eylea provides the greatest benefit in patients with vision 20/50 or worse 40% and 55% of subjects have continued macular edema at the 2 and 3 year visits, respectively, even after monthly intravitreal anti-VEGF injections The Opportunity In Treating DME The Pr

  35. Slide 35: TYBEE Design for Phase 2 DME Clinical Trial

    TYBEE Design for Phase 2 DME Clinical Trial CLS-TA Eylea Any additional treatment based on as needed criteria at Week 16 and Week 20 will be intravitreal Eylea Evaluate at 6 months Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Enrollment Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Arm

  36. Slide 36: TYBEE Met Its Primary Endpoint

    Mean change from baseline in BCVA (ETDRS letters) read Baseline BCVA in ETDRS letters: 58: control arm; 57: active arm Error bars are 90% confidence intervals of the mean TYBEE Met Its Primary Endpoint Mean Change in BCVA from baseline at Week 24; the data1 are tested for equivalence by comparing th

  37. Slide 37: Similar Visual Acuity Data Observed Through Month 6

    Similar Visual Acuity Data Observed Through Month 6 Mean change from baseline in BCVA by visit Error bars are 90% confidence intervals of the means Baseline BCVA in ETDRS letters: 58: control arm; 57: active arm Data at each visit starting from Week 4 (week 12 and Week 24 displayed) show similar out

  38. Slide 38: 1/3 as Many Treatments in the Active Arm

    1/3 as Many Treatments in the Active (Combination) Arm Resulted in Efficacy Similar to that Seen in the Monthly Eylea Arm Similar clinical and statistical improvements in BCVA at Week 12 in each arm Week 12 Data CONTROL (Eylea only) arm: Treatments given at Baseline, Month 1 and Month 2 ACTIVE (Comb

  39. Slide 39: Additional Intravitreal Eylea Required in TYBEE

    Additional Intravitreal Eylea Required in TYBEE (As needed Week 16 and 20) Number of subjects with Eylea injections in the PRN stage Number of additional Eylea Injections in the PRN stage (1) p=0.03 (2) p=0.1; although numerically this shows that half the number of patients required intravitreal Eyl

  40. Slide 40: Secondary Endpoint: Mean Change in CST

    Mean change from baseline in CST (microns) N=35 N=36 Error bars are 90% confidence intervals of the means Secondary Endpoint Mean change from baseline in CST at week 24 in microns Table 14.2.2.2.1; Listing 16.2.6.2 Baseline CST in microns: 513: control arm; 501: active arm Each arm shows a statistic

  41. Slide 41: Central Retinal Thickness by Visit

    Apparent additional improvement in retinal thickness reduction is seen from week 4 in the combination arm, and sustained through the end of the study (week 24) Central Retinal Thickness (CST) Mean change from baseline in CST by visit Mean change from baseline in CST (microns) Wk04 Wk08 Wk12 Wk16 Wk2

  42. Slide 42: 50% or Greater Reduction in Excess CST

    Percent of patients with a ≥50% reduction in excess CST Wk04 Wk08 Wk12 Wk16 Wk24 Wk20 50% or Greater Reduction in Excess CST Proportion of patients demonstrating response by retinal thickness reduction is seen from week 4 in the combination arm, and maintained through the end of the study CST: centr

  43. Slide 43: TYBEE Trial High Level Summary

    TYBEE Trial High Level Summary ETDRS: early treatment of diabetic retinopathy study; BCVA: best corrected visual acuity; CST: central subfield thickness Efficacy This Phase 2 trial met its primary endpoint. Suprachoroidal CLS-TA used together with intravitreal Eylea showed equivalent vision improvem

  44. Slide 44: A World Without Blindness: In Summary

    A WORLD WITHOUT BLINDNESS In Summary

  45. Slide 45: Patent Portfolio

    Patent No. Significance Expiration U.S. 7,918,814 Provides exclusivity for the administration of any drug to the eye by inserting a microinjector into the sclera or corneal stroma of a patient’s eye, and infusing the drug into the sclera or cornea 2029 U.S. 8,197,435 Provides exclusivity for adminis

  46. Slide 46: Leadership: Accomplished Team with Deep Ophthalmic Experience

    Leadership Accomplished Team with Deep Ophthalmic Experience Experience Years DANIEL WHITE President, CEO and Director GSK, Stiefel, CIBA Vision, Alimera 25 CHARLES DEIGNAN Chief Financial Officer AtheroGenics, AAIPharma, Schering-Plough 27 GLENN NORONHA, Ph.D. Chief Scientific Officer Alcon, Sucamp

  47. Slide 47: Major Near-Term Anticipated Milestones

    2018 2019 Uveitis RVO DME NDA review Phase 3 (SAPPHIRE) P3 Data (PEACHTREE) Phase 3 (TOPAZ) NDA Submission Publications Major Near-Term Anticipated Milestones Provide Multiple Potential Value-Inflection Points Topline P3 Data Analysis & Presentation P2 Data (TYBEE)

  48. Slide 48: Thank You!

    THANK YOU! We see a world without blindness; relentlessly pursuing transformative, elegant, precise solutions to restore and preserve vision.

Clearside Biomedical — Investor Presentation (June 2018) on 6ix